| Trial ID: | L6543 |
| Source ID: | NCT05102071
|
| Associated Drug: |
Empagliflozin
|
| Title: |
Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line Sulfonylureas
|
| Acronym: |
|
| Status: |
WITHDRAWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2|Cardiovascular Diseases
|
| Interventions: |
DRUG: empagliflozin|DRUG: metformin|DRUG: sulfonylurea
|
| Outcome Measures: |
Primary: Occurrence of first hospitalization for congestive heart failure (HHF), up to 5 years and 3 months | Secondary: Hospitalizations, up to 5 years and 3 months|Emergency department (ED) visits, up to 5 years and 3 months|Length of stay, up to 5 years and 3 months|Number of filled drugs, up to 5 years and 3 months|Outpatient visits, up to 5 years and 3 months|All cause cost, total cost of care, divided by medical (inpatient costs, outpatient costs, emergency costs) and pharmacy costs (all reported in Per Patient Per Month (PPPM) costs), up to 5 years and 3 months
|
| Sponsor/Collaborators: |
Sponsor: Boehringer Ingelheim
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
0
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2021-11-01
|
| Completion Date: |
2022-06-15
|
| Results First Posted: |
|
| Last Update Posted: |
2022-06-01
|
| Locations: |
Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, 06879, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT05102071
|
